Skip to content
cccskills
FreePublished on GitHub

enda-reduce-fludrocortisone-hypertension

Suggests reducing the fludrocortisone dose in patients who develop new-onset hypertension while on fludrocortisone replacement for primary adrenal insufficiency. Consider dose reduction when hypertension arises alongside signs of mineralocorticoid excess such as edema, weight gain, or hypokalemia.

The English summary is being prepared. Showing the original description.

Run score Not tested

See how to install

Files included (1)

  • SKILL.md2.2 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Reduce Fludrocortisone Dose if Hypertension Develops

STEP 1 — Gather Information

Measure seated blood pressure, assess for edema or weight gain, check serum sodium and potassium, review current fludrocortisone dose and timing, and screen for other hypertension causes (e.g., renal artery stenosis, essential hypertension).

STEP 2 — Rule In / Rule Out

If new hypertension coincides with fludrocortisone initiation or uptitration and is accompanied by edema, weight gain, or hypokalemia, attribute to fludrocortisone excess; otherwise evaluate for alternative etiologies before adjusting dose.

STEP 3 — Classify or Stratify

Classify hypertension severity (stage 1: 130‑139/80‑89 mmHg; stage 2: ≥140/≥90 mmHg) and confirm euvolemia (absence of orthostatic hypotension or dehydration signs) to guide dose reduction magnitude.

STEP 4 — Decide

Reduce fludrocortisone by 50‑100 µg increments, recheck blood pressure and electrolytes in 1‑2 weeks; if hypertension persists after dose reduction in a euvolemic patient, add an ACE inhibitor or ARB while avoiding diuretics and aldosterone receptor blockers.

Clinical Guardrails / Mimics / Pitfalls

Do not use diuretics or spironolactone/eplerenone as they may worsen adrenal insufficiency; avoid abrupt fludrocortisone discontinuation; monitor for fatigue, hypotension, or hyponatremia after dose reduction indicating over‑correction.

Concrete Clinical Example

A 48‑year‑old woman on fludrocortisone 100 µg daily presents with BP 152/96 mmHg, mild peripheral edema, and serum K+ 3.2 mmol/L. Fludrocortisone is reduced to 50 µg daily; after one week BP is 128/82 mmHg and K+ normalizes.

Source: Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-1710

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill